Search results for "ankylosing spondyliti"

showing 10 items of 57 documents

AUTOPHAGY, BUT NOT THE UNFOLDED PROTEIN RESPONSE, REGULATES THE EXPRESSION OF IL-23 IN THEGUT OF PATIENTS WITH ANKYLOSING SPONDYLITIS AND SUBCLINICAL…

2013

Background: IL-23 is a heterodimeric cytokine that has been implicated in the pathogenesis of Ankylosing Spondylitis (AS). High serum and tissue levels for this cytokine have been demonstrated in AS and correlated with entheseal inflammation but the mechanisms responsible for its over-expression are currently not clear. Objectives: The aim of the study was to clarify the immunological mechanisms underlying the increased IL-23 expression in the gut of AS patients. Methods: Consecutive gut biopsies from 20 HLA-B27+ AS patients and 10 normal subjects were considered for the present study. The occurrence of HLA-B27 misfolding was studied by assessing the co-localization of HLA-B heavy chains (H…

Il23 Ankylosing spondylitis;Settore MED/16 - ReumatologiaIl23 Ankylosing spondylitiSettore BIO/13 - Biologia ApplicataIl23Ankylosing spondylitis
researchProduct

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

2010

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated. ©…

MaleAntibodieReceptors Tumor Necrosis FactorEtanerceptlaw.inventionEtanerceptRandomized controlled triallawimmune system diseasesOutcome Assessment Health CareMonoclonalImmunology and Allergyskin and connective tissue diseasesAntirheumatic AgentAntibodies MonoclonalAntirheumatic AgentsTreatment OutcomeAntirheumatic AgentsFemalemedicine.drugHumanReceptormusculoskeletal diseasesAdultAnkylosingmedicine.medical_specialtyImmunologyDrug Administration ScheduleOutcome Assessment (Health Care)RheumatologyInternal medicinemedicineHumansSpondylitis AnkylosingSpondylitisSpondylitiAnkylosing spondylitisbusiness.industryTumor Necrosis Factor-alphaAnkylosing spondylitis; Etanercept; Infliximab; Adult; Antibodies Monoclonal; Antirheumatic Agents; Drug Administration Schedule; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Male; Outcome Assessment (Health Care); Receptors Tumor Necrosis Factor; Spondylitis Ankylosing; Treatment Outcome; Tumor Necrosis Factor-alpha; Rheumatology; Immunology; Immunology and Allergymedicine.diseaseInfliximabRheumatologyInfliximabClinical trialAnkylosing spondylitistomatognathic diseasesImmunoglobulin GPhysical therapybusinessTumor Necrosis Factor
researchProduct

Methotrexate induced sprue-like syndrome

2008

A 52 year-old male patient diagnosed of ankylosing spondylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate. He did not respond to treatment with oral iron not a proton pump inhibitor and an upper endoscopy was performed. The histological study of the duodenal biopsies showed villus atrophy. After removing the methotrexate, administrating intramuscular iron and undertaking a gluten-free diet, the histological and analytical alterations progressively resolved.

MalePathologymedicine.medical_specialtyDuodenummedicine.drug_classBiopsyProton-pump inhibitorCase ReportEndoscopy GastrointestinalSprueAtrophyBiopsymedicineHumansSpondylitis AnkylosingSpondylitisAnkylosing spondylitismedicine.diagnostic_testbusiness.industryGastroenterologySyndromeGeneral MedicineMiddle Agedmedicine.diseaseCeliac DiseaseMethotrexateIron-deficiency anemiaAntirheumatic AgentsMethotrexateAtrophybusinessmedicine.drugWorld Journal of Gastroenterology
researchProduct

Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients w…

2011

Side effects of TNF neutralisation - mostly infectious complications - were recognized, the most important being pulmonary tuberculosis infections. gamma/ d T cells contribute to protective immune response against mycobacterium tuberculosis.The aim of the present study was to assess the expansion capacity of Vgamma9/Vdelta2 T cells from (tuberculin purified protein derivative (PPD) positive and PPD negative) patients with active rheumatoid arthritis (RA), and to examine the in vitro effect of infliximab on this lymphocyte subset.28 PPD negative RA patients were studied and compared with 14 PPD positive RA patients, 45 PPD-negative and 110 PPD-positive healthy volunteers. Cell separation, ex…

Malelcsh:Internal medicineTuberculosisT-Lymphocyteslcsh:MedicineArthritisTuberculinArthritis RheumatoidInterferon-gammaRheumatologyPsoriasismedicineHumanslcsh:RC31-1245Tuberculosis PulmonaryCells CulturedAgedAnkylosing spondylitisInterferon-gamma productionTumor Necrosis Factor-alphabusiness.industrylcsh:RAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabAntirheumatic AgentsRheumatoid arthritisImmunologyFemaleTumor necrosis factor alphabusinessmedicine.drug
researchProduct

Molecular evidence of HLA-B27 in a historical case of ankylosing spondylitis

2005

Malemedicine.medical_specialty10017 Institute of Anatomy2745 RheumatologyImmunologyMEDLINEMolecular evidence610 Medicine & healthPolymerase Chain ReactionHistory 17th CenturyRheumatologyInternal medicinemedicineHumans2736 Pharmacology (medical)Immunology and AllergySpondylitis AnkylosingPharmacology (medical)SpondylitisHLA-B27 AntigenHLA-B27Ankylosing spondylitis2403 Immunologybusiness.industrymedicine.diseaseDermatologyRheumatologyHistory 16th CenturyAnthropologyImmunology11294 Institute of Evolutionary Medicine2723 Immunology and Allergy570 Life sciences; biologybusiness
researchProduct

THU0469-HPR Sexual perception and sexual problems in patients with ankylosing spondylitis

2013

Background Ankylosing spondylitis (AS) is a chronic, systemic inflammatory rheumatic disease affecting the axial skeleton, but may also affect peripheral joints, tendons and internal organs. This disease which begins in the second or third decade may give rise to significant loss of function and impaired quality of life. Despite the known importance of sexuality as part of quality of life (1), only a few studies have explored this important issue in AS patients. Objectives To explore sexuality in patients with AS in regard to how satisfied they are with their sexual life and whether the patients think their sexuality is influenced by the disease. Methods This is a prospective, longitudinal,…

Neither Satisfied nor Dissatisfiedmedicine.medical_specialtyAnkylosing spondylitisbusiness.industryImmunologyHuman sexualityDiseasemedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyQuality of lifeFamily medicinemedicinePhysical therapyImmunology and AllergyOutpatient clinicBASFIbusinessBASDAIAnnals of the Rheumatic Diseases
researchProduct

Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled study

1994

Abstract The efficacy and tolerability of aceclofenac and naproxen sodium in the treatment of ankylosing spondylitis (AS) were evaluated and compared in this double-blind, multicenter, controlled study. Of the 130 patients who entered the study, 126 patients met the inclusion criteria. Efficacy was evaluated at baseline, 15 days, and 1, 2, and 3 months using a visual analog scale for spontaneous pain, a zero to three-point scale for pain on movement and pain at rest, and measurements of chest expansion, hand-to-floor distance, Schober's test, and normal daily activities. No significant between-group differences were seen for any of the variables at baseline, except hand-to-floor distance. B…

PharmacologyAnkylosing spondylitisNaproxenmedicine.medical_specialtybusiness.industryVisual analogue scaleIncidence (epidemiology)Naproxen Sodiummedicine.diseaseTolerabilityAnesthesiaPhysical therapyMedicineAceclofenacPharmacology (medical)businessAdverse effectmedicine.drugCurrent Therapeutic Research
researchProduct

Minimally Invasive Sacroiliac Joint Arthrodesis: Experience in a Prospective Series with 24 Patients

2014

Background: Sacroiliac (SI) joint pain conservative treatments show poor outcomes. Hypothesis: surgical treatment will show better results. Patients and methods: Prospective series: 24 patients undergoing SI fusion after failure of medical treatment and showing temporary relief with SI infiltration. Period: Nov 2009-July 2013. Gender: 9/15. 11 cases bilaterally (all ). Age: 32-71 years (mean 47.4 years). Height: 161-178 cm (mean 168.2 cm). Weight: 56-84 kg (mean 68.4 kg). Etiology: 12 degenerative/spontaneous, 7 fall on buttocks, 3 coincident with lumbar disc and 2 with lumbar posterolateral fusion. Exclusion criteria: ankylosing spondylitis, osteitis condensans ilii, sacro-iliac joint arth…

Sacroiliac jointmedicine.medical_specialtyAnkylosing spondylitisCirurgiabusiness.industryVisual analogue scaleArthrodesismedicine.medical_treatmentOsteoarthritismedicine.diseaseArticulacions MalaltiesSurgeryOswestry Disability Indexmedicine.anatomical_structureSacroiliac joint dysfunctionJoint painMedicinemedicine.symptombusinessJournal of Spine
researchProduct

RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?

2019

Susceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2, IL12B, and IL7R) involved in IL23 driven pathways of inflammation. AS is also strongly associated with polymorphisms in two transcription factors, RUNX3 and T-bet (encoded by TBX21), which are important in T-cell development and function. The influence of these genes on the pathogenesis of AS and their potential for identifying drug targets is discussed here.

lcsh:Immunologic diseases. Allergy0301 basic medicineTBX21Mini ReviewImmunologyBiologyCD8-Positive T-Lymphocytesmedicine.disease_causeAminopeptidasesInterleukin-23Polymorphism Single NucleotideAutoimmunity03 medical and health sciences0302 clinical medicineankylosing spondylitisInterleukin 23medicineImmunology and AllergyHumansImmunologic FactorsSpondylitis AnkylosingMolecular Targeted TherapyInterleukin-7 receptorTranscription factorHLA-B27 AntigenAnkylosing spondylitistherapyAntigen processingautoimmunityReceptors Interleukinmedicine.disease3. Good healthKiller Cells Natural030104 developmental biologyCore Binding Factor Alpha 3 SubunitGene Expression RegulationinflammationImmunologylcsh:RC581-607T-Box Domain ProteinsFunctional genomicsfunctional genomics030215 immunologyFrontiers in Immunology
researchProduct

A2.2 Uveitis is not associated with cardiovascular disease risk factors in patients with ankylosing spondylitis

2014

Background and Objectives Ankylosing spondylitis (AS) is a chronic, autoimmune, systemic, inflammatory disease. Recently, a link has been established between autoimmune inflammatory diseases, incl. AS, and the risk of developing cardiovascular disease (CVD). Uveitis is the most frequent extraarticular location of AS - it occurs in about 25 - 40% of patients. The impact of evidence of uveitis during the course of AS still remains a challenge. Does AS with uveitis differ from AS without uveitis? The objective of this study was to detect the link between uveitis during the course of AS and the CVD risk factors in patients with AS. Materials and Methods 77 AS patients classified using the modif…

medicine.medical_specialtyAnkylosing spondylitisWaistbusiness.industryCholesterolImmunologyDiseasemedicine.diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySurgeryPathogenesischemistry.chemical_compoundHigh-density lipoproteinRheumatologychemistryInternal medicineImmunology and AllergyMedicinebusinessBody mass indexUveitisAnnals of the Rheumatic Diseases
researchProduct